The firm had decreased Q3 sales for precision oncology drugs including Ibrance, Tukysa, and Bosulif, but sales increased for ...

After Pfizer agreed to acquire weight-loss drug developer Metsera for $7.3 billion, Novo Nordisk swooped in with an ...

Shares of Merck (MRK) traded 1% higher on Tuesday afternoon after the company said that it has entered into a funding ...

Merck said on Tuesday that it has entered into an agreement to receive funds managed by Blackstone Life Sciences for $700 ...

The deal hands Blackstone a piece of the potential future sales of an antibody-drug conjugate that could soon challenge marketed medicines from AstraZeneca and Gilead.

Utilizing its innovative ADC payload platform, Akari is advancing a new class of immuno-oncology ADCs built on the platform ...

The startup claims its medicines may be able to overcome the limitations of conventional antibody-drug conjugates by ...

Merck (MRK) stock is in focus as the company secures $700M from Blackstone to advance cancer therapy sacituzumab tirumotecan ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the company has entered into an agreement to receive funds managed by Blackstone Life Sciences ...

NEOK Bio, Inc., a biotechnology company focused on the development of novel antibody drug conjugates (ADCs) for improving outcomes for cancer patients, announced that it has emerged from stealth mode ...

Neok Bio has exited stealth with $75 million to take a pair of bispecific antibody-drug conjugates sourced from ABL Bio into ...